Wednesday, 14 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 18, 2026

Kevin O'Leary Says No, Interest Rates Won't Ever Go Below 5% Again — But All That It Means Is… 'You're Gonna Buy A House 30% Smaller. That's All'

View original at finance.yahoo.com
Kevin O'Leary Says No, Interest Rates Won't Ever Go Below 5% Again — But All That It Means Is… 'You're Gonna Buy A House 30% Smaller. That's All' Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Interest rates in the U.S. will not be dropped dramatically due to strong economy and rising productivity

    60% confidence

  • For 40 years, 7% was a normal market mortgage rate

    60% confidence

  • Interest rates will not go below 5% again, or will take a very long time if ever

    60% confidence

  • People should stop waiting for the Federal Reserve to lower rates and should decide whether the numbers work now

    60% confidence

  • Home buyers will adapt to higher rates by buying houses that are 30% smaller

    60% confidence

  • Using more than one-third of free cash flow after tax to pay mortgage leads to financial problems

    60% confidence

  • 3.5% to 3.75% mortgage rates were an aberration, not the norm

    60% confidence

Data points we hold from this source

Elf Labs · ip assets500 trademarks_and_copyrights
Elf Labs · market expansion30 countries
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Kevin O'Leary Says No, Interest Rates Won't Ever Go Below 5% Again — But All That It Means Is… 'You're Gonna Buy A House 30% Smaller. That's All' — Source | Via News | ViaNews EU